Proto Script Pharmaceutical Stock

Proto Script Pharmaceutical EV/EBIT

EV/EBIT (Enterprise Value to EBIT) of Proto Script Pharmaceutical (PSCR) as of Aug 6, 2026.

EV/EBIT

0.00

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Proto Script Pharmaceutical is 2026 0.00 . EV/EBIT (Enterprise Value to EBIT) of Proto Script Pharmaceutical was 2025 0.00 . It decreases by % lower compared to the previous year.

The Proto Script Pharmaceutical EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2013
0.00 base
Jan 1, 2014
0.00 base
Jan 1, 2015
0.00 base
Jan 1, 2016
0.00 base
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
Jan 1, 2021
0.00 base
Jan 1, 2022
0.00 base
YEARPRICE-TO-EBIT
2022 -
2021 -
2020 -
2019 -
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 -
Access this data via the Eulerpool API
Get Free API Key

Proto Script Pharmaceutical Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Proto Script Pharmaceutical's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Proto Script Pharmaceutical's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Proto Script Pharmaceutical's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Proto Script Pharmaceutical grows earnings faster than its peers.

Proto Script Pharmaceutical Stock analysis

What does Proto Script Pharmaceutical do? Proto Script Pharmaceutical Corp is an American biotechnology company specializing in the development and manufacture of innovative, high-quality drugs. The company is focused on researching new breakthrough technologies in drug manufacturing to find potential cures and treat diseases. Their business model is based on producing medications that are highly effective and of high quality while also being cost-effective and patient-friendly. They collaborate closely with biotechnology companies and academic institutions to acquire the best technologies and develop effective and innovative drugs. They have products in the areas of neurology, endocrine health, and oncology. They have also entered into partnerships with other companies to expand and further develop their products. Overall, Proto Script Pharmaceutical Corp is a groundbreaking company in the biotechnology field with decades of experience in drug development and a commitment to improving the lives of millions of people worldwide. Proto Script Pharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Proto Script Pharmaceutical stock

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Proto Script Pharmaceutical since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Proto Script Pharmaceutical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Proto Script Pharmaceutical

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Proto Script Pharmaceutical